Abstracts tagged "Spondylarthropathies"

Abstract Number: 0348 • ACR Convergence 2020
Biologics History and Sex Are Linked to Golimumab Discontinuation in Axial Spondyloarthritis: A Sub-Analysis of the Post-Registration GO-Practice Study
Philippe Bertin¹, Philippe Goupille², Florence Tubach³, Eric Lespessailles⁴, Naoual Harid⁵, Saannya Sequeira⁶, Jean-Marie Fayette⁶, Bruno Fautrel⁷ and Rene-Marc Flipo⁸, ¹Limoges University Hospital, Limoges, France, ²CHU Tours, department of rheumatology, Tours, France, ³Pierre Louis Institute of Epidemiology and Public Health, INSERM 1136, Sorbonne University and Centre of Pharmacoepidemiology, Pitié Salpêtrière Hospital, APHP.Sorbonne University, Paris, Ile-de-France, France, ⁴Regional Hospital and University of Orleans, Orléans, France, ⁵MSD France Puteaux, Puteaux, Ile-de-France, France, ⁶ClinSearch, Malakoff, Ile-de-France, France, ⁷Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁸Lille University Hospital, Lille, France
Background/Purpose: Golimumab (GLM) is the latest anti-TNFα to be indicated for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). The post-registration GO-PRACTICE…
Abstract Number: 1339 • ACR Convergence 2020
COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Rebecca Haberman¹, Rochelle Castillo¹, Alan Chen², Di Yan¹, Deborah Ramirez², Vaish Sekar², Robert Lesser², Gary Solomon², Andrea Neimann², Rebecca Blank¹, Peter Izmirly³, Dan Webster⁴, Alexis Ogdie⁵, Andrea Troxel², Samrachana Adhikari² and Jose Scher¹, ¹NYU School of Medicine, New York City, ²NYU Langone Health, New York City, ³New York University, New York, NY, ⁴Sage Bionetworks, Seattle, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The COVID-19 pandemic has quickly emerged as the most challenging global health crisis in a generation. Affecting initially China, New York City (NYC) quickly…
Abstract Number: 1886 • ACR Convergence 2020
Measuring Physical Activity in AxSpA:Content Validity and Measurement Properties of the New AxSpA-SQUASH
Marllies Carbo¹, Davy Paap², Fiona Maas¹, Mark Siderius³, Hendrika Bootsma¹, Freke Wink³, Suzanne Arends³ and Anneke Spoorenberg³, ¹University Medical Centre Groningen, Groningen, Netherlands, ², Department of Rehabilitation Medicine, University of Medical Centre Groningen, Groningen, Netherlands, ³University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: The ASAS-EULAR recommendations for management of axial Spondyloarthritis (axSpA) includes that patients should be encouraged to exercise. There is no validated instrument for measuring…
Abstract Number: 0543 • ACR Convergence 2020
Exercise Among Older Adults Living with Rheumatic Disease: Physical Activity Habits and Patient Reported Outcomes
Alexis Ogdie¹, Sofia Pedro², Joshua Baker³, Kaleb Michaud⁴ and Patricia Katz⁵, ¹University of Pennsylvania, Philadelphia, PA, ²FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita, ⁵University of California, San Francisco, Novato, CA
Background/Purpose: Among patients with rheumatic disease, physical activity is important for maintaining health and improving outcomes. EULAR recommendations suggest at least 30 min of vigorous…
Abstract Number: 1342 • ACR Convergence 2020
Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK
Filip Van den Bosch¹, Peter Nash², James Cheng-Chung Wei³, Francisco Blanco⁴, Vassilis Tsekouras⁵, Chuanbo Zang⁶, Daniela Graham⁷, Edmund Arthur⁸, Pamela Selema⁶, Bonnie Vlahos⁶ and Atul Deodhar⁹, ¹Ghent University Hospital, Ghent, Belgium, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ⁴INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruna, Spain, ⁵Pfizer, Nicosia, Cyprus, ⁶Pfizer, Collegeville, PA, ⁷Pfizer, Groton, PA, ⁸Pfizer, Peapack, NJ, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Etanercept (ETN) is effective and well tolerated in patients with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is limited information on the effects of withdrawing…
Abstract Number: 1887 • ACR Convergence 2020
Spinal Mobility and Function: How Closely Do They Associate in Axial Spondyloarthropathy?
Sinead Maguire¹, Phil Gallagher² and Finbar O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²St Vincents University Hospital, UCD, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is a form of inflammatory arthritis affecting the axial skeleton. Persistent disease activity can result in restricted spinal mobility over time,…
Abstract Number: 0548 • ACR Convergence 2020
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up
Maria Auxiliadora Martin-Martinez¹, Santos Castañeda², Fernando Sanchez-Alonso³, Carmen García-Gómez⁴, Carlos González_Juanatey⁵, M. Ángeles Belmonte-López⁶, Jesus Tornero-Molina⁷, José Santos-Rey⁸, Carmen Olga Sánchez-González⁹, Estefania Moreno¹⁰, Maria del puerto Moreno-Gil¹¹, Tatiana Cobo-Ibañez¹², Jose Antonio Pinto-Tasende¹³, Jesús Babío-Herráez¹⁴, Gema Bonilla¹⁵, Antonio Juan-Mas¹⁶, Francisco Manero-Ruiz¹⁷, Montserrat Romera-Baurés¹⁸, Javier Bachiller-Corral¹⁹, Eugenio Chamizo-Carmona²⁰, Javier Calvo-Catalán²¹, Raimon Sanmartí²², Celia Erausquin-Arruabarrena²³, Rosario Garcia-Vicuña²⁴, Carmen Barbadillo²⁵, Sergio Ros-Expósito²⁶, Ana Isabel Turrión²⁷, M José González-Fernández²⁸, Jose Miguel Senabre²⁹, Silvia Martínez-Pardo³⁰, Ana Ruibal-Escribano³¹, Emilio Giner-Serret³², Elisabet Berzosa-Sola³³, Julia Martínez-Barrio³⁴, Encarnación Pagán³⁵, M Enriqueta- Peiró³⁶, Sagrario Bustabad-Reyes³⁷, Alba Erra-Durán³⁸, Beatriz González Álvarez³⁹, Ana Cruz Valenciano⁴⁰, Javier Rivera-Redondo⁴¹, Manuel Moreno Ramos⁴², Sergio Rodriguez Montero⁴³, Mercedes Morcillo-Valle⁴⁴, Maria Teresa Navío⁴⁵, Maria Galindo-Izquierdo⁴⁶, Manuel Riera-Soler⁴⁷, Jordi Fiter⁴⁸, Javier Llorca⁴⁹ and Miguel Ángel González-Gay⁵⁰, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, ⁴Consorci Sanitari de Terrassa, Barcelona, Spain, ⁵Hospital Lucus Augusti, Lugo, Spain, ⁶Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁷University Hospital of Guadalajara. Spain, Madrid, Madrid, Spain, ⁸Hospital Virgen de la Salud, Toledo, Spain, ⁹Hospital Sureste, Madrid, Spain, ¹⁰Universitario Vall D'hebron, Barcelona, Spain, ¹¹Complejo Hospitalario de Cáceres, Caceres, Spain, ¹²Hospital Infanta Sofia, Madrid, Spain, ¹³CHUAC, A Coruña, Spain, ¹⁴Hospital de Cabueñes, Gijón, Spain, ¹⁵Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ¹⁶Hospital Sont Llatzer, Palma de Mallorca, Spain, ¹⁷Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁰Hospital de Merida, Badajoz, Spain, ²¹Hospital General Universitario Valencia, Valencia, Spain, ²²Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ²³Hospital de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ²⁴Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶Hospital Viladecans, Barcelona, Spain, ²⁷Hospital Universitario de Salamanca, Salamanca, Spain, ²⁸Hospital Dexeus, Barcelona, Spain, ²⁹Hospital de Marina Baixa, Alicante, Spain, ³⁰H. Mutua de Terrassa, Barcelona, Catalonia, Spain, ³¹Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ³²Hospital Obispo Polanco, Teruel, Spain, ³³Hospital del Elda, Alicante, Spain, ³⁴Hospital General Universitario Gregorio Marañón, Madrid, ³⁵Hospital Los Arcos, Murcia, Spain, ³⁶Hospital Marques de Valdecilla, Santander, Spain, ³⁷Hospital Universitario Canarias, Tenerife, Spain, ³⁸Hospital San Rafael, Barcelona, Spain, ³⁹Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain, ⁴⁰Hospital Severo Ochoa, Madrid, Spain, ⁴¹Instituto Provincial de Rehabilitación, Madrid, Spain, ⁴²Hospital Virgen de la Arrixaca, Murcia, Spain, ⁴³H. Virgen de Valme, Sevilla, Spain, ⁴⁴Hospital El Escorial, Madrid, Spain, ⁴⁵Hospital Infanta Leonor, Madrid, Spain, ⁴⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴⁷Hospital dos de Maig, Barcelona, Spain, ⁴⁸Hospital Universitario Son Dureta, Palma de Mallorca, Spain, ⁴⁹School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵⁰Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular (CV) event (CVE) in patients with chronic inflammatory rheumatic diseases…
Abstract Number: 1354 • ACR Convergence 2020
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis
Mark Siderius¹, Freke Wink¹, Anneke Spoorenberg¹ and Suzanne Arends¹, ¹University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…
Abstract Number: 1888 • ACR Convergence 2020
Successful Evaluation of Spinal Mobility Measurements with the Epionics SPINE Device in Patients with Axial Spondyloarthritis Compared to Controls
David Kiefer¹, Xenofon Baraliakos², Daniela Adolf³, Varvara Chatzistefanidi⁴, Ilka Schwarze⁵, Uwe Lange⁶, Jan Brandt-Jürgens⁷, Edgar Stemmler⁸, Sabine Sartingen⁸ and Juergen Braun⁹, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ³StatConsult, Magdeburg, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, ⁵Rheumazentrum Leipzig, Leipzig, ⁶Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ⁷Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ⁸AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany, ⁹Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) comprising radiographic (r-) and non-radiographic (nr)-axSpA is often associated with loss of mobility and impaired physical function. Established assessments of spinal…
Abstract Number: 0553 • ACR Convergence 2020
The US Prevalence of Ulcerative Colitis Associated Peripheral Arthralgias and Arthritis: Data from the National Health & Nutrition Examination Survey (NHANES)
Oleg Stens¹, Hyun-seok Kim², Jason Hou² and Michael Weisman³, ¹Harbor-UCLA Medical Center, San Diego, CA, ²Baylor College of Medicine, Houston, TX, ³Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: An association between ulcerative colitis (UC) and peripheral arthritis has been known since the 1930’s and more recently has been described as a part…
Abstract Number: 1370 • ACR Convergence 2020
A Delayed Effect of Tumor Necrosis Factor Inhibitors on Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort
Denis Poddubnyy¹, Valeria Rios Rodriguez², Murat Torgutalp², Ani Dilbaryan², Maryna Verba², Mikhail Protopopov², Fabian Proft², Judith Rademacher², Hildrun Haibel², Joachim Sieper² and Martin Rudwaleit³, ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany
Background/Purpose: There are inconclusive data on the effect of tumor necrosis factor inhibitors (TNFi) on radiographic spinal progression in axial spondyloarthritis (axSpA). Although inflammation and…
Abstract Number: 2013 • ACR Convergence 2020
Substantial Lifetime Risk of Developing Ankylosing Spondylitis (Axial Spondyloarthritis) for Relatives. Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort
Sjef van der Linden¹, Peter Villiger², Zhixiu Li³, Matthew Brown⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶ and Muhammad Khan⁷, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ²Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ³Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ⁴Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: Familial occurrence of ankylosing spondylitis (AS) is well known. Our follow-up study aimed at assessing the incidence of clinically defined AS among first degree…
Abstract Number: 0897 • ACR Convergence 2020
Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept
Xenofon Baraliakos¹, Annette Szumski², Kenneth Kwok³ and Bonnie Vlahos⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Syneos Health, Princeton, ³Pfizer, New York, NY, ⁴Pfizer, Collegeville, PA
Background/Purpose: Treatment with etanercept (ETN) is effective and well tolerated in patients with axial spondyloarthritis (AS), but the time frames within which patients tend to…
Abstract Number: 1376 • ACR Convergence 2020
Impact of Body Composition Measures on the Response to Biological Disease-modifying Anti-rheumatic Drugs in Patients with Ankylosing Spondylitis
Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Burkhard Muche¹, Anne-Katrin Weber¹, Susanne Lüders¹, Hildrun Haibel¹, Maryna Verba¹, Joachim Sieper¹ and Denis Poddubnyy², ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Data on the impact of body weight and body mass index (BMI) on the response to biological disease-modifying anti-rheumatic drugs (bDMARDs) in axial spondyloarthritis…
Abstract Number: 2014 • ACR Convergence 2020
The Relative Diagnostic Utility of Inflammatory Back Pain Criteria in an Inception Cohort of Patients with Psoriasis, Iritis, and Colitis Presenting with Undiagnosed Back Pain
Georg Kröber¹, Ulrich Weber², Raj Carmona³, James Yeung⁴, Jon Chan⁵, Sibel Aydin⁶, Liam Martin⁷, Ariel Masetto⁸, Stephanie Keeling⁹, Olga Ziouzina⁷, Sherry Rohekar¹⁰, Rana Dadashova¹¹, Joel Paschke¹¹, Amanda Carapellucci¹¹, Robert G Lambert¹² and Walter Maksymowych⁹, ¹University of Southern Denmark, Sønderborg, Denmark, ²University of South Denmark, Odense, Denmark, ³St. Joseph's Healthcare, Hamilton, ON, Canada, ⁴James Yeung Rheumatology, Vancouver, BC, Canada, ⁵Artus Health Clinic, Vancouver, BC, Canada, ⁶University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Lawson Health Research Institute, London, ON, Canada, ¹¹CARE Arthritis, Edmonton, AB, Canada, ¹²University of Alberta and CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: Patients with psoriasis, iritis, or colitis and back pain represent a high-risk population for the presence of axial spondyloarthritis (axSpA). Clinicians rely on the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].